Burlington, Vt.-based startup CoreMap has secured $10.5 million in a Series A funding round led by Qure Ventures. Founded in 2016, CoreMap is taking aim at atrial fibrillation (AF) with technology designed to map complex arrhythmias inside the heart. The company’s patented system combines an electrode pair design in a high-density array configuration with algorithm-driven […]
OrbiMed
OrbiMed founder Isaly lodges defamation suit against newspaper, reporter
OrbiMed founder Sam Isaly sued the newspaper and reporter who published a story last year about his alleged sexual harassment of women employed at his his private equity fund. Reporter Damien Garde’s story, which ran Dec. 5, 2017, on the Boston Globe‘s STAT website, quoted six former employees who accused Isaly of routinely demeaning and harassing […]
Orbimed founder Isaly resigns on harassment accusations
OrbiMed founder and managing partner Sam Isaly made it official last week when he relinquished control of the private equity fund in the wake of sexual harassment allegations lodged by several former employees. Six former employees accused Isaly, a 72-year-old investor long revered in the biotech community for his ability to pick stocks, of routinely demeaning and […]
OrbiMed founder Isaly out after harassment allegations
OrbiMed founder and managing partner Sam Isaly yesterday stepped down in the wake of sexual harassment allegations lodged by several former employees of the healthcare hedge fund. In a statement released last night, New York City-based OrbiMed said Isaly is leaving “pursuant to years-long succession planning discussions” and did not address the accusations from six women, first […]
Report: Investors review hedge fund involvement in wake of harassment allegations against Orbimed founder Isaly
Institutional investors with positions in OrbiMed are reportedly reviewing their involvement with the healthcare hedge fund after sexual harassment allegations surfaced against founder and managing partner Sam Isaly. Six former employees of biotech hedge fund accused Isaly, a 72-year-old investor long revered in the biotech community for his ability to pick stocks, of routinely demeaning and harassing women with […]
Report: OrbiMed founder Sam Isaly harassed women for years, according to former employees
Several former employees of biotech hedge fund OrbiMed have alleged that Sam Isaly, the firm’s founder & managing partner, sexually harassed his female colleagues for years, according to an investigation by STAT. Isaly is a 72-year-old investor who has long been revered among the biotech community for his ability to pick stocks. But at OrbiMed, former […]
Orbimed closes $551m Asia-focused healthcare fund
OrbiMed said this week it closed its 3rd Asian-focused healthcare private equity fund, having raised approximately $551 million in capital commitments. The new fund, the Asia Partners III, is slated to invest “broadly across the Asian healthcare industry,” focusing on growth stage product and services-oriented companies in China and India, according to the investment firm. […]
ViewRay raises $14m in private placement
ViewRay (NSDQ:VRAY) said today that it raised nearly $14 million in a private placement as it gears up to launch its MRIdian linear accelerator, saying it expects to win regulatory nods in the U.S. and overseas by the end of the year. Cleveland-based ViewRay said the round was led by existing backers OrbiMed Advisors, Xeraya Capital and Kearny Venture […]
OrbiMed launches $950m healthcare fund
OrbiMed said it closed another venture capital fund worth $950 million that it plans to deploy on about 30 companies in the medical device, biopharmaceutical, diagnostics and healthcare IT markets. The New York-based VC giant said its OrbiMed Private Investments VI fund will put up investments ranging from $10 million to $75 million. Last year OrbiMed floated a $924 […]
OrbiMed floats $924m healthcare fund
OrbiMed said today that it raised a $924 million fund to invest in healthcare companies, following the flotation of a $735 million fund back in November 2013.
